In the genetic analysis, we observed that genetically proxied lifelong SGLT2 inhibition reduced total, advanced, and early-onset prostate cancer in the general male population by 44%, 48%, and 73%, respectively. This evidence concerns the gene SLC5A2 and Familial prostate cancer.